Welcome to our dedicated page for Hutchmed (China) SEC filings (Ticker: HCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the next trial milestone or royalty clause inside HUTCHMED’s labyrinth of biotech disclosures can feel impossible. If you have ever typed “HUTCHMED SEC filings explained simply” or hunted down a single R&D footnote in a 300-page report, you know the challenge.
Stock Titan solves it. Our AI reviews every submission the moment it hits EDGAR, then surfaces what matters—so you can read an entire HUTCHMED annual report 10-K simplified in minutes, not hours. Need the latest HUTCHMED quarterly earnings report 10-Q filing or a fast HUTCHMED earnings report filing analysis? They’re here, paired with plain-English summaries and side-by-side financial trends. Wondering about management deals? We stream HUTCHMED Form 4 insider transactions real-time and flag unusual HUTCHMED executive stock transactions Form 4 before the market reacts.
Use the platform to:
- Track HUTCHMED insider trading Form 4 transactions instantly
- Spot trial updates inside every 8-K with HUTCHMED 8-K material events explained
- Compare pay packages in the latest HUTCHMED proxy statement executive compensation
- Speed-read complex risk factors by understanding HUTCHMED SEC documents with AI
Whether you follow oncology catalysts, cash runway, or manufacturing scale-ups, our real-time alerts, expert commentary, and AI-powered summaries keep you ahead of the curve—so you make decisions with confidence instead of skimming PDFs at midnight.
HUTCHMED (China) Limited filed a Form 6-K for June 2025 containing three exhibits.
- Exhibit 99.3: Announces Chinese regulatory approval for ORPATHYS® in combination with TAGRISSO® to treat lung-cancer patients with MET amplification who have progressed after first-line EGFR inhibitor therapy. This represents a new therapeutic option and the only materially substantive development in the filing.
- Exhibit 99.1: A block-listing six-monthly return, an administrative Hong Kong Stock Exchange requirement detailing potential share issuances under existing schemes.
- Exhibit 99.2: Disclosure of the company’s current total voting rights, providing an updated share count for investors.
The approval disclosed in Exhibit 99.3 could meaningfully expand HUTCHMED’s oncology portfolio and addressable patient base in mainland China, whereas Exhibits 99.1 and 99.2 are routine corporate housekeeping items with no immediate financial metrics or transactions reported.
FAQ
What is the current stock price of Hutchmed (China) (HCM)?
What is the market cap of Hutchmed (China) (HCM)?
What is the core business of HUTCHMED (China) Limited?
Which segments does the company operate in?
How does HUTCHMED drive innovation in the biopharmaceutical industry?
What is the significance of their clinical research and regulatory achievements?
What distinguishes HUTCHMED in a competitive market?
How does the company ensure quality and compliance in its operations?
Can you elaborate on the company’s market impact?
How is HUTCHMED positioned relative to its competitors in biopharmaceutical innovation?
